Home » Newsletters » BioWorld Science

BioWorld Science

July 9, 2009

View Archived Issues

Longer vaccination interval with recombinant malaria vaccine leads to higher immunogenicity

Losartan a possible therapy for AGTR1-overexpressing breast cancer

Prasugrel reduces several types of myocardial infarction in TRITON-TIMI 38 trial

Phenylbutyrate a potential treatment for Alzheimer's disease

Merrimack initiates dosing in phase I/II clinical study of MM-111 in cancer

FDA approves Hyperion's SPA for phase III clinical trial of HPN-100 in adults with UCD

NovaBiotics receives clearance to initiate first-in-man clinical trials of Novexatin

Kuros initiates treatment in phase IIb clinical trial of KUR-211 in diabetic foot ulcers

DermaGen completes patient enrollment in phase I/IIa trial of antimicrobial peptide DPK-060

Bayer submits NDA to FDA for oral contraceptive estradiol valerate/dienogest

Japanese MHLW approves Novartis' Rasilez for high blood pressure

Pluristem begins enrollment for phase I clinical trial of PLX-PAD in critical limb ischemia

ARYx Therapeutics reports results from EmbraceAC phase II/III clinical trial of tecarfarin

Avanir completes enrollment in open-label extension of phase III STAR trial of Zenvia

Ikaria obtains worldwide exclusive license to BioLineRx's BL-1040 for AMI

Peplin completes enrollment in phase III trials of PEP-005 for actinic keratoses

Daiichi Sankyo launches new formulations of antibacterial agent Cravit in Japan

Cell Therapeutics to meet with EMEA in September 2009 to discuss MAA for Opaxio

Shire files treatment protocol with FDA for velaglucerase alfa for Gaucher disease

Univ. California, Clear Vascular patent peptides for the treatment of vascular plaques

Novel cannabinoid CB2 receptor ligands patented by Ipsen Pharma

Hameln rds describes novel ACAT inhibitors for the treatment of lipoprotein disorders

GlaxoSmithKline describes dual histamine H1 and H3 receptor antagonists

Novel inhibitor may allow physiological understanding of fatty acid elongase 6

Wyeth's Enbrel approved in Japan for juvenile idiopathic arthritis indication

Thallion suspends enrollment for phase II trial of TLN-232 due to dispute with licensor

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026